semaglutide and heart health VisualAbstract: improves symptoms in patients with failure Obesity drug brings heart health

In a new Phase 2 trial, patients who took Wegovy (semaglutide) plus bimagrumab lost 22.1% of their body weight in just 48 weeks

Semaglutide is not recommended for patients with severe gastroparesis

In pooled STEP 1-3 data on the 2.4 mg dose, nausea occurred in 43.9% (vs 16.1% placebo), diarrhea in 29.7% (vs 15.9%), vomiting in 24.5% (vs 6.3%), and constipation in 24.2% (vs 11.1%)

That is a significant overdose

"Semaglutide in type 2 diabetes is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF)

Weight loss occurred progressively during the first 60 weeks, and was maintained for the rest of the trial